Publications by authors named "P Wiklund"
Background And Objectives: Enhanced Recovery After Surgery (ERAS) guidelines for Radical Cystectomy (RC) were published over ten years ago. Aim of this systematic review is to update ERAS recommendations for patients undergoing RC and to give an expert opinion on the relevance of each single ERAS item.
Methods: A systematic review was performed to identify the impact of each single ERAS item on RC outcomes.
Article Synopsis
- The study aimed to assess the outcomes of robot-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder in women with bladder cancer, specifically focusing on functionality, cancer results, and complications.
- The research involved 146 female patients, revealing that about half underwent pelvic organ-preserving procedures, achieving overall daytime and nighttime continence rates of 54% and 53%.
- The findings concluded that RARC with orthotopic neobladder offers good functional outcomes, with pelvic organ preservation improving urinary continence while maintaining cancer safety.
Objective: To assess recurrence-free survival (RFS) in patients with undetectable tumour-informed circulating tumour DNA (ctDNA) before radical cystectomy (RC) and evaluate if those who converted from detectable to undetectable ctDNA status after RC have similar RFS outcomes as those with persistently undetectable ctDNA status.
Patients And Methods: Patients who underwent RC had prospectively and longitudinally collected tumour-informed ctDNA analyses during 2021-2023. ctDNA status was informed from the pre-RC specimen.
Purpose: Understanding the specific tumor characteristics associated with detectable circulating tumor DNA (ctDNA) in patients with renal cell carcinoma (RCC) is critical for informing future studies aiming to establish the clinical utility of such testing. We characterized the pathologic and clinical features associated with preoperatively detectable ctDNA in patients with renal masses suspicious for RCC.
Methods: Consecutive patients who underwent partial or radical nephrectomy for nonmetastatic suspected RCC (cT1b-T3) during 2022-2023 had prospectively collected tumor-informed ctDNA analyses conducted preoperatively and postoperatively.
Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus
September 2024
Background And Objective: Sequential intravesical gemcitabine/docetaxel (Gem/Doce) has emerged as a potential alternative to bacillus Calmette-Guérin (BCG) for the treatment of non-muscle-invasive bladder cancer (NMIBC). Our aim was to determine the comparative effectiveness of BCG and Gem/Doce for patients with intermediate-risk (IR) NMIBC, composed mainly of high-grade (HG) Ta disease.
Methods: Patients with IR-NMIBC who received either BCG or Gem/Doce during 2013-2023 were included.